https://www.selleckchem.com/pr....oducts/ziritaxestat.
Fentanyl buccal soluble film (FBSF), a new formulation of fentanyl, is developed for the treatment of breakthrough pain (BTP) in opioid-tolerant patients with cancer. This study aimed to assess the feasible dose range of FBSF required for Taiwanese population. This was an open-label, multicenter, noncomparative study. Cancer patients who were aged 20years or older and had a stable regimen equivalent to 60 to 1000mg/day of oral morphine, 20 to 120mg/day of intravenous morphine, or 25 to 300μg/h of transdermal fentanyl for at least 1
Like
Comment
Share
